



Novogen Announces Presentation at Rodman & Renshaw 16th Annual Healthcare Conference

SYDNEY (September 4, 2014) – Novogen Ltd. (ASX: NRT, NASDAQ: NVGN) today announced that Graham Kelly PhD, CEO, will present at the Rodman & Renshaw 16th Annual Healthcare Conference on Wednesday, September 10th in New York. Dr. Kelly will provide an overview of the two Novogen first-in-class drug technology platforms in the field of oncology. His presentation will take place at the New York Palace Hotel and will begin at 10:25am.

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc, with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on the Company's website, www.novogen.com.

For more information please contact:

Corporate Contact

Executive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2 9472 4100

Investors enquiries

In the USA:

Lazar Partners
Novogen@lazarpartners.com
+1 212-867-1762

Media enquiries

In the USA:

Lazar Partners
Novogen@lazarpartners.com
+1 212-867-1762

In Australia:

Dr. Douglas Pretsell
Instinctif Partners
+61 (0) 3 9657 0706

In ROW:

Sue Charles
Instinctif Partners
+44 (0) 20 7457 2020